308
Although the t-AML developed following oral etoposide therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated.
 the child: Subject; child: Subject.Age; the t-AML: Effect; oral etoposide therapy: Treatment; high-dose, multiagent chemotherapy: Treatment; etoposide: Treatment.Drug; chemotherapy: Treatment.Drug; oral: Treatment.Route; high-dose: Treatment.Dosage; chemotherapy: Combination.Drug; etoposide: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 the child: Subject; child: Subject.Age; the t-AML: Effect; oral etoposide therapy: Treatment; high-dose, multiagent chemotherapy: Treatment; etoposide: Treatment.Drug; chemotherapy: Treatment.Drug; oral: Treatment.Route; high-dose: Treatment.Dosage; chemotherapy: Combination.Drug; etoposide: Combination.Drug